Sara Pessina

  • Citations Per Year
Learn More
The current standard treatment for glioblastoma (GB) involves surgery, radiotherapy and chemotherapy with temozolomide (TMZ) and is associated with an overall survival (OS) of 14.6 mo. Phase I/II clinical trials of anti-GB immunotherapy have demonstrated the feasibility and the safety of this approach. Moreover, immune-mediated antitumor responses have been(More)
Abcc3, a member of the ATP-binding cassette transporter superfamily, plays a role in multidrug resistance. Here, we found that Abcc3 is highly expressed in blood-derived NK cells but not in CD8(+) T cells. In GL261 glioma-bearing mice treated with the alkylating agent temozolomide (TMZ) for 5 d, an early increased frequency of NK cells was observed. We also(More)